The FDA approved a 7.2 mg high‑dose formulation of Novo Nordisk’s semaglutide injection (Wegovy HD) under a commissioner’s voucher that expedited review to roughly 54 days. Novo won clearance for adults to reduce and maintain excess weight using the higher dose; the agency cited the voucher program to accelerate the timetable. The lead sentence: regulators cleared a stronger Wegovy dose after an unusually short review enabled by a political‑era voucher program. Trial data Novo shared showed high‑dose Wegovy produced greater weight loss than the original 2.4 mg regimen and delivered results broadly in line with competitive GLP‑1/GIP programs. The approval follows Novo’s November agreement with the White House to lower GLP‑1 prices, which was tied to the voucher award; that sequence has attracted scrutiny from critics concerned about policy optics. The clearance reshapes market dynamics: Wegovy HD gives Novo a tool to reclaim share against Eli Lilly’s Zepbound and other next‑generation agents. Payers, rivals and clinicians will track real‑world uptake, label positioning and any post‑market safety monitoring required by FDA.